Plasma Cell Myeloma Pre-Analysis Cell Sorting, Bone Marrow
Use
This test is useful for the pre-analysis cell sorting involved in the MayoComplete Plasma Cell Myeloma panel. It plays a crucial role in identifying additional abnormalities in multiple myeloma (MM) that are of prognostic and potentially therapeutic value. The application of targeted next-generation sequencing-based analysis aids in the risk categorization of MM, providing valuable information for patient diagnosis and treatment planning.
Special Instructions
This test is not orderable independently and is performed as a reflex. It is specifically linked to the NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies test. Ensure the specimen is fresh as the test involves cell sorting.
Limitations
Testing can only be performed on fresh bone marrow specimens, and certain conditions can cause the specimen to be rejected. These include gross hemolysis, fully clotted samples, and paraffin-embedded tissues. Additionally, the test requires a minimum plasma cell percentage of 1% in the sample.
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 22637-3
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
2 mL
Container
Lavender or pink top (EDTA) or yellow top (ACD)
Collection Instructions
Ensure a minimum plasma cell percentage of 1%. Invert the tube several times to mix the sample. Send in the original tube without aliquoting and label as bone marrow.
Causes for Rejection
Gross hemolysis, fully clotted samples, bone marrow biopsies, slides, paraffin shavings, frozen tissues, paraffin-embedded tissues, paraffin-embedded bone marrow aspirates, and extracted DNA
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |